Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with